Clinical Trial Update: A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase II trial evaluating upfront radiotherapy plus almonertinib for EGFR-mutant non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: EGFR Positive Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN